Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial

OBJECTIVE: To evaluate the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal growth factor receptor inhibitor (EGFRI)-induced intense pruritus. DESIGN: Randomised, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, Bruno, Trower, Mike, Duggal, Ajay, Guglielmini, Pamela, Harris, Peter, Jackson, David, Lacouture, Mario E, Ratti, Emiliangelo, Tonini, Giuseppe, Wood, Andrew, Ständer, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045265/
https://www.ncbi.nlm.nih.gov/pubmed/32034016
http://dx.doi.org/10.1136/bmjopen-2019-030114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045265/
https://www.ncbi.nlm.nih.gov/pubmed/32034016
http://dx.doi.org/10.1136/bmjopen-2019-030114

Ejemplares similares